Sagimet Biosciences Prices $115 Million Common Stock Offering

Key Facts

1Sagimet Biosciences announced the pricing of an underwritten offering of 8.75 million Series A common shares at $10.00 per share.

2The company expects gross proceeds from the offering to be approximately $115.0 million before expenses.

3The offering is expected to close on or about October 1, 2026, subject to customary conditions.

Sagimet Biosciences announced the pricing of an underwritten offering of 8.75 million Series A common shares at $10.00 per share. Reuters reported that the company expects gross proceeds from the offering to be approximately $115.0 million before expenses. The offering is expected to close on or about October 1, 2026, subject to customary conditions.

The capital raise is intended to fund the development of therapeutics for metabolic and fibrotic pathways. Shares of SGMT closed at $9.33 on September 29, 2026, having traded between a high of $9.92 and a low of $9.25 during that session.